556 related articles for article (PubMed ID: 33285283)
21. Efficacy of COVID convalescent plasma therapy in hospitalized moderate coronavirus disease 2019 patients.
Irawan C; Rumende CM; Sukrisman L; Pitoyo CW; Suwarto S; Susilo A; Mulansari NA; Harahap AT; Priantono D; Syafitri R; Chunaeni S; Ritchie NK
J Infect Dev Ctries; 2023 Jan; 17(1):43-51. PubMed ID: 36795929
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
[TBL] [Abstract][Full Text] [Related]
23. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
24. A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19.
Chauhan L; Pattee J; Ford J; Thomas C; Lesteberg K; Richards E; Bernas CA; Loi M; Dumont L; Annen K; Berg M; Zirbes M; Knight V; Miller A; Jenkins TC; Bennett TD; Monkowski D; Boxer RS; Beckham JD
Clin Infect Dis; 2022 Aug; 75(1):e466-e472. PubMed ID: 34549274
[TBL] [Abstract][Full Text] [Related]
25. Convalescent Plasma the Experience and Journey from Blockbuster to Incognito: A Single Centre Experience.
Negi G; Kaur D; Jain A; Mohan YK; Meinia SK; Kaur P; Panda PK; Kalita D; Ravikant
Recent Adv Antiinfect Drug Discov; 2023; 18(3):188-196. PubMed ID: 35733306
[TBL] [Abstract][Full Text] [Related]
26. Multi-institutional experience with COVID-19 convalescent plasma in children.
Jacquot C; Gordon O; Noland D; Donowitz JR; Levy E; Jain S; Willis Z; Rimland C; Loi M; Arrieta A; Annen K; Drapeau N; Osborne S; Ardura MI; Arora S; Zivick E; Delaney M
Transfusion; 2023 May; 63(5):918-924. PubMed ID: 36965173
[TBL] [Abstract][Full Text] [Related]
27. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
[TBL] [Abstract][Full Text] [Related]
28. Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience.
Ateş İ; Erden A; Güven SC; Gürler EK; Çağlayan A; Güçbey Ö; Apaydın H; Şahiner ES; Küçük H; Varan Ö; Omma A; Küçükşahin O
Transfus Apher Sci; 2021 Dec; 60(6):103238. PubMed ID: 34412949
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.
Kirenga B; Byakika-Kibwika P; Muttamba W; Kayongo A; Loryndah NO; Mugenyi L; Kiwanuka N; Lusiba J; Atukunda A; Mugume R; Ssali F; Ddungu H; Katagira W; Sekibira R; Kityo C; Kyeyune D; Acana S; Aanyu-Tukamuhebwa H; Kabweru W; Nakwagala F; Bagaya BS; Kimuli I; Nantanda R; Buregyeya E; Byarugaba B; Olaro C; Mwebesa H; Joloba ML; Siddharthan T; Bazeyo W
BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34376401
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
31. Treatment of COVID-19 Patients with Two Units of Convalescent Plasma in a Resource-Constrained State.
Ipe TS; Ugwumba B; Spencer HJ; Le T; Ridenour T; Armitage J; Ryan S; Pearson S; Kothari A; Patil N; Dare R; Crescencio JCR; Venkata A; Laudadio J; Mohammad K; Jamal N; Thompson J; McNew H; Gibbs M; Hennigan S; Kellar S; Reitzel K; Walser BE; Novak A; Quinn B
Lab Med; 2022 Nov; 53(6):623-628. PubMed ID: 35771890
[TBL] [Abstract][Full Text] [Related]
32. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
[TBL] [Abstract][Full Text] [Related]
33. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
[TBL] [Abstract][Full Text] [Related]
34. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
35. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
Yoon HA; Bartash R; Gendlina I; Rivera J; Nakouzi A; Bortz RH; Wirchnianski AS; Paroder M; Fehn K; Serrano-Rahman L; Babb R; Sarwar UN; Haslwanter D; Laudermilch E; Florez C; Dieterle ME; Jangra RK; Fels JM; Tong K; Mariano MC; Vergnolle O; Georgiev GI; Herrera NG; Malonis RJ; Quiroz JA; Morano NC; Krause GJ; Sweeney JM; Cowman K; Allen S; Annam J; Applebaum A; Barboto D; Khokhar A; Lally BJ; Lee A; Lee M; Malaviya A; Sample R; Yang XA; Li Y; Ruiz R; Thota R; Barnhill J; Goldstein DY; Uehlinger J; Garforth SJ; Almo SC; Lai JR; Gil MR; Fox AS; Chandran K; Wang T; Daily JP; Pirofski LA
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33476300
[TBL] [Abstract][Full Text] [Related]
36. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis.
Troxel AB; Petkova E; Goldfeld K; Liu M; Tarpey T; Wu Y; Wu D; Agarwal A; Avendaño-Solá C; Bainbridge E; Bar KJ; Devos T; Duarte RF; Gharbharan A; Hsue PY; Kumar G; Luetkemeyer AF; Meyfroidt G; Nicola AM; Mukherjee A; Ortigoza MB; Pirofski LA; Rijnders BJA; Rokx C; Sancho-Lopez A; Shaw P; Tebas P; Yoon HA; Grudzen C; Hochman J; Antman EM
JAMA Netw Open; 2022 Jan; 5(1):e2147331. PubMed ID: 35076699
[TBL] [Abstract][Full Text] [Related]
37. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
[TBL] [Abstract][Full Text] [Related]
38. Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials.
Huaman MA; Raval JS; Paxton JH; Mosnaim GS; Patel B; Anjan S; Meisenberg BR; Levine AC; Marshall CE; Yarava A; Shenoy AG; Heath SL; Currier JS; Fukuta Y; Blair JE; Spivak ES; Petrini JR; Broderick PB; Rausch W; Cordisco M; Hammel J; Greenblatt B; Cluzet VC; Cruser D; Oei K; Abinante M; Hammitt LL; Sutcliffe CG; Forthal DN; Zand MS; Cachay ER; Kassaye SG; Ram M; Wang Y; Das P; Lane K; McBee NA; Gawad AL; Karlen N; Ford DE; Laeyendecker O; Pekosz A; Klein SL; Ehrhardt S; Lau B; Baksh SN; Shade DM; Casadevall A; Hanley DF; Ou J; Gniadek TJ; Ziman A; Shoham S; Gebo KA; Bloch EM; Tobian AAR; Sullivan DJ; Gerber JM
Transfusion; 2023 Sep; 63(9):1639-1648. PubMed ID: 37534607
[TBL] [Abstract][Full Text] [Related]
39. Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.
Agrawal A; Jha T; Gogoi P; Diwaker P; Goel A; Khan AM; Saxena AK
Transfus Apher Sci; 2022 Dec; 61(6):103455. PubMed ID: 35618641
[TBL] [Abstract][Full Text] [Related]
40. Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma.
Estcourt LJ; Cohn CS; Pagano MB; Iannizzi C; Kreuzberger N; Skoetz N; Allen ES; Bloch EM; Beaudoin G; Casadevall A; Devine DV; Foroutan F; Gniadek TJ; Goel R; Gorlin J; Grossman BJ; Joyner MJ; Metcalf RA; Raval JS; Rice TW; Shaz BH; Vassallo RR; Winters JL; Tobian AAR
Ann Intern Med; 2022 Sep; 175(9):1310-1321. PubMed ID: 35969859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
